DOP11 Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
Stephanie Slevin(John Radcliffe Hospital), Satish Keshav(John Radcliffe Hospital), Kate D. Lynch(Royal Adelaide Hospital), Daniel JB Marks(Age UK), Min Tan(Zunyi Medical University), Karen Leavens(GlaxoSmithKline (United Kingdom)), Naren Srinivasan(Age UK), Alessandra Geremia(John Radcliffe Hospital), Borgel Greenaway(John Radcliffe Hospital), Katherine Nevin(GlaxoSmithKline (United Kingdom)), Stephen Hughes(GlaxoSmithKline (United Kingdom)), Simon Travis(University of Oxford), L M Wang(SingHealth), C Arancibia(University of Oxford), Conor Lahiff(Beth Israel Deaconess Medical Center), Ruth M. Tarzi(Hammersmith Hospital)
Cited by 1
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
|The Journal of Experimental Medicine|2011|623
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
|Gut|2006|603
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558